THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006(1), and in particular Article 37(5) thereof,
Whereas:
(1) Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC(2).
(2) Proposals for new or updated harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA, as well as on the comments received from the parties concerned, it is appropriate to introduce or update harmonised classification and labelling of certain substances by amending Annex VI to that Regulation.
(3) With regard to the substance nitric acid … % (EC number: 231-714-2), new scientific data has been made available for the hazard class ‘acute toxicity’ which suggests that the classification for this hazard class as recommended in the RAC opinion, which is based on older data, might not be appropriate. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until RAC has issued an opinion on the new information, while all other classes covered by the earlier opinion should be included.
(4) With regard to the substance phenol, dodecyl-, branched (EC number: 310-154-3), the RAC is in the process of adopting a new opinion for the specific concentration limits to be applied to the hazard class ‘toxic for reproduction’. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until that opinion is finalised.
(5) Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. In addition, a certain period of time will be necessary to allow suppliers to comply with the registration obligations resulting from the new harmonised classifications for substances classified as carcinogenic, mutagenic or toxic to reproduction, categories 1A and 1B (Table 3.1) and categories 1 and 2 (Table 3.2), or as very toxic to aquatic organisms which may cause long term effects in the aquatic environment, in particular with those set out in Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council(3).
(6) In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.
(7) The measures provided for in this Regulation are in accordance with the opinion of the Committee established under Article 133 of Regulation (EC) No 1907/2006,
HAS ADOPTED THIS REGULATION:
Annex VI to Regulation (EC) No 1272/2008 is amended in accordance with the Annex to this Regulation.
By way of derogation from Article 3(2), the harmonised classifications set out in Annex to this Regulation may be applied before the date referred to in Article 3(2).
1.This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
2.Article 1 shall apply in respect of substances and mixtures from 1 January 2017.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 24 July 2015.
For the Commission
The President
Jean-Claude Juncker
Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
Table 3.1 is amended as follows:
the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:
| Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||
| 007-004-00-1 | nitric acid … % | 231-714-2 | 7697-37-2 | Ox. Liq. 2 Skin Corr. 1A | H272 H314 | GHS03 GHS05 Dgr | H272 H314 | EUH071 | Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 99 % > C ≥ 65 % | B |
| 015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 | Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Eye Dam. 1 Aquatic Acute 1 | H260 H300 H311 H330 H318 H400 | GHS02 GHS06 GHS05 GHS09 Dgr | H260 H300 H311 H330 H318 H400 | EUH029 EUH032 | M = 100 | |
| 031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 | Repr. 1B Carc. 1B STOT RE 1 | H360F H350 H372 (respiratory and haematopoietic systems) | GHS08 Dgr | H360F H350 H372 (respiratory and haematopoietic systems) | |||
| 050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — | Repr. 1B Acute Tox. 3 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H360FD H301 H312 H372** H315 H319 H400 H410 | GHS08 GHS06 GHS09 Dgr | H360FD H301 H312 H372** H315 H319 H410 | * STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,25 % ≤ C < 1 % Skin Irrit. 2; H315:C ≥ 1 % Eye Irrit. 2; H319:C ≥ 1 % M = 10 | A 1 | |
| 603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 | Flam. Liq. 2 Carc. 2 Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 | H225 H351 H302 H312 H332 H335 H315 H319 | GHS02 GHS08 GHS07 Dgr | H225 H351 H302 H312 H332 H335 H315 H319 | |||
| 603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H361d*** H302 H400 H410 | GHS08 GHS07 GHS09 Wng | H361d*** H302 H410 | M = 1 M = 10 | ||
| 606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 | Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d*** H400 H410 | GHS08 GHS09 Wng | H361d*** H410 | M = 10 M = 100 | ||
| 607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 | Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 | H315 H319 H412 | GHS07 Wng | H315 H319 H412 | |||
| 613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 | Carc. 2 Acute Tox. 3 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 1 | H351 H301 H332 H318 H410 | GHS08 GHS06 GHS05 GHS09 Dgr | H351 H301 H332 H318 H410 | M = 10 | ||
| 613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 | Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (liver) H314 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Dgr | H361d H373 (liver) H314 H317 H410 | EUH071 | M = 1 M = 1 | |
| 613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 | Carc. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H317 H410 | M = 1 M = 1 | ||
| 613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 | Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 | H331 H301 H400 H410 | GHS06 GHS09 Dgr | H331 H301 H410 | M = 1 000 M = 1 000 | ||
the following entries are inserted in accordance with the order of the entries set out in Table 3.1:
| Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||
| 019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Eye Irrit. 2 | H319 | GSH07 Wng | H319 | |||
| 604-092-00-9 | phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2] | 310-154-3 [1] | 121158-58-5 [1] 74499-35-7 [2] | Skin Corr. 1C Aquatic Acute 1 Aquatic Chronic 1 | H314 H400 H410 | GHS05 GHS09 Dgr | H314 H410 | M = 10 M = 10 | ||
| 606-148-00-8 | carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] | 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] | 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] | Skin Sens. 1 | H317 | GHS07 Wng | H317 | |||
| 606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | — | 335104-84-2 | Repr. 2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d H373 (eyes, kidneys, liver) H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361d H373 (eyes, kidneys, liver) H317 H410 | M = 100 M = 10 | ||
| 607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 (kidneys) H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H373 (kidneys) H317 H410 | M = 1 M = 1 | ||
| 607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 | Skin Corr. 1C Aquatic Chronic 3 | H314 H412 | GHS05 Dgr | H314 H412 | |||
| 607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 | Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 | H315 H319 H412 | GHS07 Wng | H315 H319 H412 | |||
| 607-710-00-5 | 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. 1B | H360FD | GHS08 Dgr | H360FD | |||
| 607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 | Repr. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H361fd H335 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361fd H335 H319 H317 H410 | M = 1 M = 1 | ||
| 607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 | Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Chronic 1 | H361d H373 (liver) H314 H317 H410 | GHS08 GHS05 GHS07 GHS09 Dgr | H361d H373 (liver) H314 H317 H410 | EUH071 | M = 1 | |
| 607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 | Acute Tox. 3 Acute Tox. 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H301 H330 H317 H400 H410 | GHS06 GHS09 Dgr | H301 H330 H317 H410 | M = 100 M = 1 000 | ||
| 607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 100 M = 10 | ||
| 607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 | STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H373 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H373 H317 H410 | M = 1 M = 1 | ||
| 613-319-00-0 | imidazole | 206-019-2 | 288-32-4 | Repr. 1B Acute Tox. 4 Skin Corr. 1C | H360D H302 H314 | GHS08 GHS07 GHS05 Dgr | H360D H302 H314 | |||
| 613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 10 M = 10 | ||
| 616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1 | ||
| 616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 | Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H373 (eyes, kidneys) H400 H410 | GHS08 GHS09 Wng | H351 H373 (eyes, kidneys) H410 | M = 1 000 M = 100 | ||
| 616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 | Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Wng | H302 H317 H410 | M = 10 M = 10 | ||
| 616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Acute Tox. 4 | H302 | GHS07 Wng | H302 | |||
| 616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | M = 1 M = 1 | ||
Table 3.2 is amended as follows:
the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:
| Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes |
|---|---|---|---|---|---|---|---|
| 007-004-00-1 | nitric acid … % | 231-714-2 | 7697-37-2 | O; R8 C; R35 | O; C R: 8-35 S: (1/2-)26-28- 36/37/39-45-63 | O; R8: C ≥ 65 % C; R35: C ≥ 20 % C; R34: 5 % ≤ C < 20 % | B |
| 015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 | F; R15/29 T+; R26/28 Xn; R21 R32 Xi; R38-41 N; R50 | F; T+; N R: 15/29-21-26/28-32-38-41-50 S:(1/2-)26-28-30-36/37/39-43-45-60-61 | N; R50: C ≥ 0,25 % | |
| 031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 | Repr. Cat. 2; R60 Carc. Cat. 2; R45 T; R48/23 | T R: 45-48/23-60 S: 45-53 | E | |
| 050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — | Repr. Cat. 2; R60-61 T; R25-48/23/25 Xn; R21 Xi; R36/38 N; R50-53 | T; N R: 21-25-36/38-48/23/25-50/53-60-61 S: 45-53-60-61 | T; R25: C ≥ 2,5 % Xn; R22: 0,25 % ≤ C < 2,5 % Xn: R21: C ≥ 1 % T; R48/23/25: C ≥ 1 % Xn; R48/20/22: 0,25 % ≤ C < 1 % Xi; R36/38: C ≥ 1 % N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % | A 1 |
| 603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 | F; R11 Carc. Cat. 3; R40 Xn; R20/21/22 Xi; R36/37/38 | F; Xn R: 11-20/21/22-36/37/38-40- S: (2-)9-16-29-36/37-46 | ||
| 603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 | Repr. Cat. 3; R63 Xn; R22 N; R50-53 | Xn; N R: 22-50/53-63 S: (2-)22-36/37-60-61 | N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 % | |
| 606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 | Repr. Cat. 3; R63 N; R50-53 | Xn; N R: 50/53-63 S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % | |
| 607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 | Xi; R36/38 N; R51-53 | Xi; N R: 36/38-51/53 S: (2-)46-61 | ||
| 613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 | Carc. Cat. 3; R40 Xn; R20/22 Xi; R41 N; R51-53 | Xn; N R: 20/22-40-41-51/53 S: (2-)26-36/37/39-46-61 | ||
| 613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 | Repr. Cat. 3; R63 C; R34 R43 N; R50-53 | C; N R: 34-43-50/53-63 S: (1/2-)26-28-36/37/39-45-60-61 | C; R34: C ≥ 10 % Xi; R36/37/38: 5 % ≤ C < 10 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % | |
| 613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 | Carc. Cat. 3; R40 Xn; R22 R43 N; R50-53 | Xn; N R: 22-40-43-50/53 S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % | |
| 613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 | T; R23/25 N; R50-53 | T; N R: 23/25-50/53 S: (1/2-)36/37-45-60-61 | N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52-53: 0,00025 % ≤ C < 0,0025 % |
the following entries are inserted in accordance with the order of the entries set out in Table 3.2:
| Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes |
|---|---|---|---|---|---|---|---|
| 019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Xi; R36 | Xi R: 36 S: (2-)25-46 | ||
| 604-092-00-9 | phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2] | 310-154-3 [1]-[2] | 121158-58-5 [1] 74499-35-7 [2] | C; R34 N; R50-53 | C; N R: 34-50/53 S: (1/2-)26-36/37/39-45-61 | N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % | |
| 606-148-00-8 | carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] | 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] | 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] | R43 | Xi R: 43 S: (2-)24-37 | ||
| 606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | 335104-84-2 | Repr. Cat. 3; R63 Xn; R48/22 R43 N; R50-53 | Xn; N R: 43-48/22-50/53-63 S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % | ||
| 607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 | Xn; R48/22 R43 N; R50-53 | Xn; N R: 43-48/22-50/53 S: (2-)24-37-46-60-61 | N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % | |
| 607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 | C; R34 N; R51-53 | C; N R: 34-51/53 S: (1/2-)26-36/37/39-45-61 | ||
| 607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 | Xi; R36/38 N; R51-53 | Xi; N R: 36/38-51/53 S: (2-)25-46-61 | ||
| 607-710-00-5 | 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. Cat. 2; R60-61 | T R: 60-61 S: 53-45 | ||
| 607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 | Repr. Cat. 3; R62-63 Xi; R36/37 R43 N; R50-53 | Xn; N R: 36/37-43-50/53-62-63 S: (2-)36/37-60-61 | Xi; R43: C ≥ 0,1 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % | |
| 607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 | Repr. Cat. 3; R63 C; R34 R43 N; R51-53 | C; N R: 34-43-51/53-63 S: (1/2-)26-28-36/37/39-45-61 | C; R34: C ≥ 10 % Xi: R36/37/38: 5 % ≤ C < 10 % | |
| 607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 | T+; R26 Xn; R22 R43 N; R50-53 | T+; N R: 22-26-43-50/53 S: (1/2-)28-36/37-45-60-61-63 | N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % | |
| 607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 | Carc. Cat. 3; R40 N; R50-53 | Xn; N R: 40-50/53 S: (2-)36/37-60-61 | N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % | |
| 607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 | R43 N; R50-53 | Xi; N R: 43-50/53 S: (2-)24-37-60-61 | N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % | |
| 613-319-00-0 | imidazole | 206-019-2 | 288-32-4 | Repr. Cat 2; R61 Xn; R22 C; R34 | T; C R: 22-34-61 S: 53-45 | ||
| 613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 | Carc. Cat. 3; R40 N; R50-53 | Xn; N R: 40-50/53 S: (2-)36/37-60-61 | N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % | |
| 616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 | N; R50-53 | N R: 50/53 S: 60-61 | N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 % | |
| 616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 | Carc. Cat. 3; R40 Xn; R48/22 N; R50-53 | Xn; N R: 40-48/22-50/53 S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52/53: 0,00025 % ≤ C < 0,0025 % | |
| 616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 | Xn; R22 R43 N; R50-53 | Xn; N R: 22-43-50/53 S: (2-)24-37-60-61 | N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % | |
| 616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Xn; R22 | Xn R: 22 S: (2-)46 | ||
| 616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 | Xn; R22 N; R50-53 | Xn; N R: 22-50/53 S: (2-)60-61 | N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % |
Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (OJ 196, 16.8.1967, p. 1).
Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).